Skip to Main Content

Author Details

Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
1989
257
83
PMIDPaper TitleJournal TitlePublished Year
36635273CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.Nat Commun2023
37801168Fourteenth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer.J Mammary Gland Biol Neoplasia2023
37902007Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.EMBO Mol Med2023
37620984MIND the translational gap: Preclinical models of ductal carcinoma in situ.Clin Transl Med2023
37478847Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens.Mol Cell2023
37651235Mouse intraductal modeling of primary ductal carcinoma in situ.STAR Protoc2023
37642941MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.J Exp Med2023
37256941FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks.Sci Adv2023
37450065Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research.J Mammary Gland Biol Neoplasia2023
37116492A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.Cancer Cell2023
37209095Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.Cell Rep2023
37029129Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Nat Commun2023
34872965A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.Cancer Res2022
35804890Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases.Cancers (Basel)2022
35715861Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.Breast Cancer Res2022
36239017Correction: Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.Clin Cancer Res2022
36323660MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.Nat Commun2022
36050473Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.Nature2022
35146447Functional genetic dropout screens and <i>in vivo</i> validation of candidate therapeutic targets using mouse mammary tumoroids.STAR Protoc2022
33429291The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice.Curr Opin Genet Dev2021
35419484Filling in the gaps in PARP inhibitor-induced synthetic lethality.Mol Cell Oncol2021
33819647Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate.Mol Cell Proteomics2021
33810010Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.Cancers (Basel)2021
34555355Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.Mol Cell2021
34548335A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.Cancer Res2021
34771558Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.Cancers (Basel)2021
34298817PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.Cancers (Basel)2021
34272384Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.Nat Commun2021
34216544Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.Mol Cell2021
33952518SMARCAD1-mediated active replication fork stability maintains genome integrity.Sci Adv2021
34358459Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.Mol Cell2021
34285417Understanding and overcoming resistance to PARP inhibitors in cancer therapy.Nat Rev Clin Oncol2021
32117586Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.Oncoimmunology2020
32060147Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.Cancer Res2020
31930530In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.EMBO J2020
32075943BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.Sci Transl Med2020
31879358TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.Genes Dev2020
33142090How the COVID-19 pandemic highlights the necessity of animal research.Curr Biol2020
33004253ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.Ann Oncol2020
32961149How the COVID-19 pandemic highlights the necessity of animal research.Curr Biol2020
32846126Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.Cell Rep2020
32391125Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.Oncotarget2020
30530501Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.Cancer Res2019
31729597Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.J Mammary Gland Biol Neoplasia2019
31185216Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.Cancer Cell2019
31367040Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.Nature2019
31444332Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.Nat Commun2019
31218575GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.J Mammary Gland Biol Neoplasia2019
31015319PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.Cancer Discov2019
31036541EZH2 Is Overexpressed in <i>BRCA1</i>-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.Clin Cancer Res2019
  • 1 - 50 of 257

Recommended Authors

Patrick C O'Leary
University of California San Francisco
Career Start Year 2010
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 3
Amanda R Wasylishen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 1
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 13
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 8
Daniel Schramek
University of Toronto
Career Start Year 2005
Number of shared co-authors 12
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 6
Justin Cidado
Oncology R&D
Career Start Year 2003
Number of shared co-authors 2
Monte M Winslow
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 2
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 2
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 2
Nuala McCabe
Queen's University Belfast
Career Start Year 2001
Number of shared co-authors 3
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 10
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 1
Sandra Burkett
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 1
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 6
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 7
Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 2
Samuel Aparicio
University of British Columbia
Career Start Year 1993
Number of shared co-authors 45
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 3
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 21
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 4
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 6
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 9
Eldad Zacksenhaus
University of Toronto
Career Start Year 1988
Number of shared co-authors 4
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 19
Alvaro N A Monteiro
H. Lee Moffitt Cancer Center & Research Institute
Career Start Year 1985
Number of shared co-authors 17
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 13

Collaborators

Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 37
David J Adams
Wellcome Sanger Institute
Co-authored papers 19
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 10
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 8
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 8
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 7
Connie R Jimenez
Co-authored papers 6
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 6
Paul J van Diest
University Medical Center Utrecht
Co-authored papers 5
Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers 5
Jeroen de Ridder
Center for Molecular Medicine, University Medical Center Utrecht
Co-authored papers 5
Elisabetta Marangoni
Co-authored papers 5
Oscar M Rueda
University of Cambridge
Co-authored papers 5
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 5
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Co-authored papers 4
Edwin Cuppen
Hartwig Medical Foundation
Co-authored papers 4
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 4
Allan Bradley
The Wellcome Trust Sanger Institute
Co-authored papers 4
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 4
Haico van Attikum
Leiden University Medical Center
Co-authored papers 4
Fr??d??ric Amant
Netherlands Cancer Institute
Co-authored papers 4
Marc Vooijs
Maastricht University Medical Centre+
Co-authored papers 4
Serena Nik-Zainal
Early Cancer Institute, University of Cambridge
Co-authored papers 3
Emilie Vinolo
CNRS URA 5
Co-authored papers 3
Daniel Zingg
Netherlands Cancer Institute
Co-authored papers 3
Anne-Claude Gingras
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 3
Jane Rogers
The Wellcome Trust Sanger Institute
Co-authored papers 3
Els Hermans
Netherlands Cancer Institute
Co-authored papers 3
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 3
Release 1.2